Eli Lilly reaps rewards of Novo acquisition
By acquiring Dicerna, Novo Nordisk has sent DKK 700m (USD 107m) into the hands of its competitor Eli Lilly in the form of returns on shares in the acquired company, which Lilly co-owns.
by marketwire, translated by daniel pedersen
On Thursday, Novo Nordisk annouced that it is acquiring the US-based biotech company Dicerna for USD 3.3bn.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly and Boehringer drug gets head start at FDA
For subscribers
Huge acquisition scores Novo Nordisk an FDA-ready treatment
For subscribers
Novo Nordisk acquires Dicerna for USD 3.3bn
For subscribers
.jpg&w=384&q=75)
